Phaseline

Companies › Verve Therapeutics

Verve Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Metabolic and endocrine; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VERVE-102
Base-editing technology designed to disrupt PCSK9 gene expression in the liver
PCSK9Phase 1Heterozygous Familial HypercholesterolemiaOct 2027
VERVE-201
Base-editing technology to inactivate ANGPTL3 gene expression in hepatocytes
ANGPTL3Phase 1HypercholesterolemiaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06164730VERVE-102Phase 1Heterozygous Familial HypercholesterolemiaCardiovascularOct 2027
NCT06451770VERVE-201Phase 1HypercholesterolemiaMetabolic and endocrineDec 2027

Targets

PCSK9 (1) ANGPTL3 (1)

Companies with the same targets

Regeneron Pharmaceuticals Novartis AstraZeneca NewAmsterdam Pharma Amgen Merck & Co. (MSD) Innovent Biologics (Suzhou) Hasten Biopharmaceutical Visirna Therapeutics HK Eddingpharm (Zhuhai)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.